Reaction

Cutaneous T-Cell Lymphoma Refractory reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 21 reports · 1 co-occurring drugs

As of the last recalculation, Cutaneous T-Cell Lymphoma Refractory appears in 21 FAERS reports alongside 1 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 634.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brentuximab Vedotin	5	634.3	634.6

Related reactions

Drug Ineffective
Off Label Use
Death
Nausea
Fatigue

Data source: openFDA FAERS. See the OpenPV methodology and limitations.